Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States.
And if the British government refuses, the manufacturer may walk away from the market.
The drug maker’s posture portends good news for American patients.
Read more at Newsmax© 2025 Newsmax. All rights reserved.